Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran etexilate for VTE prevention in total knee replacement
NCT00246025Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dabigatran etexilate oral solution in venous thromboembolism (VTE) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants Who Have a Composite Endpoint Consisting of Total Venous Thromboembolic Event (VTE) and All Cause Mortality at 2 weeks. Started Oct 2005; status: completed.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00246025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00246025.